USPTO Delivers Setback To Genentech

Law360, New York (February 22, 2007, 12:00 AM EST) -- In a blow for Genentech Inc., regulators at the United States Patent & Trademark Office have called into question the patent at the center of the biotech’s longstanding royalty battle with MedImmune Inc. over an infant respiratory drug.

On Wednesday, Genentech revealed that the USPTO had issued a final office action in its reexamination of the company's so-called Cabilly II patent, rejecting the patentability of the claims.

Genentech is currently locked in a battle with biotech rival MedImmune over the intellectual property that covers a process...
To view the full article, register now.